|
One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab
|
Dec 2020
|
European Journal of Haematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology
|
Dec 2020
|
Journal of Managed care and specialty pharmacy
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs
|
Dec 2020
|
Journal of Managed care and specialty pharmacy
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease
|
Dec 2020
|
Journal of Managed care and specialty pharmacy
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
|
Dec 2020
|
Cancer Medicine
|
myelodysplastic syndromes (MDS)
|
|
Current and emerging strategies for management of myelodysplastic syndromes
|
Dec 2020
|
Blood reviews
|
myelodysplastic syndromes (MDS)
|
|
Allogeneic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes and Prevention of Relapse
|
Jan 2021
|
Clinical Lymphoma , Myeloma & Leukemia
|
myelodysplastic syndromes (MDS)
|
|
The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia
|
Jan 2021
|
Seminars in Hematology
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
|
Jan 2021
|
Journal of clinical oncology: official journal of the American Society Clinical Oncology
|
myelodysplastic syndromes (MDS)
|
|
Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS)
|
Jan 2021
|
Cancer Causes & Control : CCC
|
myelodysplastic syndromes (MDS)
|
